Linda Anne DiMeglio, MD, MPH

Linda Anne DiMeglio, MD, MPH

Associate Professor of Pediatrics
Director of Career Development and Co-Chair of the Pediatric Protocol Development Team: Indiana University Clinical and Translational Science Institute

Phone: (317) 944-3889
Email: dimeglio [at] iu.edu
Riley Hospital for Children
705 Riley Hospital Drive, Rm 2620
Indianapolis IN 46202



Pediatric Endocrinology and Diabetology

Areas of Interest

My areas of interest in my clinical practice include metabolic bone and calcium disorders and type 1 diabetes treatment and prevention.

After graduating from Harvard University with honors, Dr. DiMeglio obtained her MD from the University of Pennsylvania in Philadelphia, PA and performed her residency in Pediatrics at Children’s Memorial Hospital (Northwestern University) in Chicago, IL.  She completed her fellowship in Pediatric Endocrinology and received her Master’s in Public Health from Indiana University-Purdue University, Indianapolis.  Since her fellowship, Dr. DiMeglio has been working in clinical research with a focus on Type 1 diabetes prevention and treatments, including new technologies and therapies for metabolic bone disease.  She currently directs Riley Hospital’s participation in a number of type 1 diabetes research networks and supervises a research staff of 5 nurses and three technicians.  She also collaborates on a variety of other translational and clinical research projects.  She is an active clinician, seeing patients with diabetes and endocrine disorders in clinics, and she teaches medical students, residents, housestaff, and fellows.


1993 MD University of Pennsylvania School of Medicine
2006 MPH Indiana University School of Medicine

Honors & Awards

2013 (Winter) HealthTap Top Pediatric Endocrinologist in the US (Honorable Mention) Award
2012-2013 Listed as one of America's Top Doctors (Castle Connolly, US News)
2010-2011, 2013 Listed as one of Indianapolis Monthly Magazine's "Top Doctors"
2011, 2008 Listed as one of "America's Best Doctors" (Best Doctors, Inc)
2008 Listed as one of "America's Top Pediatricians" (Consumers' Research Council of America)
2007, May Induction into the Beta Zeta chapter of Delta Omega (National Public Health Honor Society)
2006 Special Guest.  Osteogenesis Imperfecta Foundation Regional Reception.
2004 Recipient – American Diabetes Association, Indiana Affiliate Outstanding Volunteer Service Award.


Riley Hospital Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN  46202

Riley Children's Specialty Clinic
11590 North Meridian Street
Suite 300
Carmel, IN 46032

South Bend Pediatrics
211 North Eddy Street
South Bend, IN 46617 

Research & Grants

Dr. DiMeglio's research is focused on Type 1 diabetes projects as well as on metabolic bone disorders.   Her primary diabetes studies are prevention studies (through Type 1 Diabetes TrialNet), studies of immunomodulatory therapies in persons with new onset diabetes (through the Immune Tolerance Network and other networks), studies on the use of new technologies in diabetes, and registry studies of persons with established diabetes (Type 1 Diabetes Exchange).  She is also researching biomarkers of type 1 diabetes onset and progression.  Dr. DiMeglio's bone studies include research trials in persons with osteogenesis imperfecta, x-linked hypophosphatemic rickets, and hypophosphatasia.

Current Grants

Type 1 Diabetes TrialNet at Indiana University Clinical Center, U01, NIH/NICHD, Principlel Investigator

Indiana Clinical and Translational Sciences Institute, U01, NIH/NCRR, Co-Investigator

Type 1 Diabetes Exchange, Contract, JAEB Foudation for Health Research, Site PI and Co-Chair of Publications and Protocols for the Network.

The Collaborative Network for Clinical Research in Immune Tolerance, Contract, NIAID, Site PI

Effect of metabolic control at onset of diabetes on progression of type 1 diabetes, U01, NIH/NICHD, Site PI

International Maternal Pediatric Adolescent AIDS Clinical Trial, UM1, NIH/NIAID, Co-Investigator/Protocol Endocrinologist

Representative PublicationsView All Publications

1. Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottleib PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russel WE, Pickney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, and the T1DAL Study Team. Targeting effector memory T cells with alefacept in new onset type 1 diabetes: 12 month results from the T1DAL study. Lancet: Diabetes and Endocrinology. Published Online 9/23/2013.

2. Williams PL, Abzug MJ, Jacobson DL, Wang J, VanDyke RB, Hazra R, Patel K, DiMeglio LA, McFarland EJ, Silio M, Borkowsky W, Seage GR, Oleske JM, and Geffner ME for the International Maternal Pediatric and Adolescent AIDS Clinical Trials P219/219C Study and the PediatricHIV/AIDS Cohort Study. Pubertal Onset in HIV-infected Children in the Era of Combination Antiretroviral Treatment. AIDS. 2013 27(12): 1959-70.

3. Wood JR, Miller KM, Maahs DM, Beck RW, DiMeglio LA, Libman IM, Quinn M, Tamborlane WV, Woerner SE for the T1D Exchange Clinic Network. Most youth with type 1 diabetes do not meet ADA or ISPAD clinical guidelines in the T1D Exchange Clinic Registry. Diabetes Care. 2013 July 36(7):2035-7. PMID 23340893.

4. Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups (DiMeglio, LA – member of writing committee). The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated within 1 week of Type 1 Diabetes Diagnosis. Diabetes Technology and Therapuetics. 2013. 15(5):401-8. PMID 23570538.

5. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland RA, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Canakinumab Study Group and Pikersgill L, deKoning E, Zeigler AG, Bohm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T on behalf of the AIDA study group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicenter, randomized double-masked, placebo-controlled trials. Lancet, 2013. 381:1905-15. PMID 23562090 NIHMS503723

6. Cabrera SM, Srivastava NT, Behzadi JM, Pottorff TM, DiMeglio LA, Walvoord EC. Long-term glycemic control as a result of initial education for children with new onset T1D: does the setting matter? Diabetes Educ. 2013 Mar-Apr;39(2):187-94. PMID: 23427241

7. Cabrera SM, DiMeglio LA, Eugster EA. Incidence and Characteristics of Pseudoprecocious Puberty in Children Presenting with Severe Primary Hypothyroidism. Journal of Pediatrics. 2013 Mar;162(3):637-92012. PMID 23196132.

8. Hanna KM, Weaver MT, Stump TE, Slaven JE, Fortenberry JD, DiMeglio LA. Readiness for living independently among emerging adults with Type 1 diabetes. Diabetes Educator. 2013 Jan; 39(1):92-9. PMID 23150530.

9. DiMeglio LA, Wang J, Siberry GK, Miller TL, Geffner ME, Hazra R, Borkowsky W, Chen JS, Dooley L, Patel K, Van Dyke RB, Fielding RA, Gurmu Y, and Jacobson DL for the Pediatric HIV/AIDS Cohort Study (PHACS). Bone Mineral Density in Children and Adolescents with Perinatal HIV Infection. 2013. AIDS. 27(2):211-220. PMID: 23032412

10. Hanna KM, Weaver MT, Stump TE, DiMeglio LA, Miller AR, Crowder S, Fortenberry JD. Initial Findings: Primary Diabetes Care Responsibilities among Emerging Adults with Type 1 Diabetes Post High School and Move Out of Parent Home. 2013 Jan; 39(1):61-8. PMID:22017460

11. Siberry GK, Williams PL, Mendez H, Seage GR, Jacobson DL, Hazra R, Rich KC, Griner R, Tassiopoulos K, Kacanek D, Mofenson LM, Miller T, DiMeglio LA, Watts DH. Safety of Tenofovir Use during Pregnancy: Early Growth Outcomes in HIV-Exposed Uninfected Infants. 2012. AIDS, 26 (9), 1151-9. PMC3476702

12. Miller, TL, Borkowsky W, DiMeglio LA, Dooley L, Geffner ME, Hazra R, McFarland EJ, Mendez AJ, Patel K, Siberry GK, VanDyke RB, Worrell CJ, Jacobson DL for the Pediatric HIV/AIDS Cohort Study. Metabolic Abnormalities and Viral Replication are Associated with Biomarkers of Vascular Dysfunction in HIV-Infected Children. HIV Medicine 2012. 13(5):264-75. PMC3297698

13. Geffner ME, Patel K, Miller TL, Hazra R, Silio M, VanDyke RB, Borowsky W, Worrell C, DiMeglio LA, and Jacobson DL for the Pediatric HIV/AIDS Cohort Study. Factors Associated with Insulin Resistance among Children and Adolescents Perinatally-Infected with HIV-1 in the Pediatric HIV/AIDS Cohort Study (PHACS). Hormone Research in Pediatrics. 2011. 76(6):386-91. PMC3697231

14. Jacobson DL, Patel K, Siberry GK, VanDyke RB, DiMeglio LA, Geffner ME, Chen JS, McFarland EJ, Borowsky W, Silio M, Fielding RA, Siminski S, Miller TL. Body Fat Distribution in Perinatally HIV-infected and HIV-exposed but Uninfected Children: Associations with Antiretroviral Therapy (ARV). American Journal of Clinical Nutrition. 2011. 94(6):1485-95. PMC3252548

15. Tu W, Eckert GJ, DiMeglio LA, Yu Z, Jung J, Pratt JH. Intensified Effect of Adiposity on Blood Pressure in Overweight and Obese Children: New Evidence for Leptin as Mediator? Hypertension. 2011. 58(5):818-24. PMC3433397

16. Weaver CM, Campbell WW, Teegarden D, Craig BA, Martin BR, Singh R, Braun MM, Apolzan JW, Hannon TS, Schoeller DA, DiMeglio LA, Hickey Y, Peacock M. Calcium, Dairy Products, and Energy Balance in Overweight Adolescents: A Controlled Trial. American Journal of Clinical Nutrition. 2011. 94(5):1163-70. PMC3192471

17. Hannon TS, DiMeglio LA, Pfefferkorn MD, Carroll AE, and Denne SC. Effects of Recombinant Human Growth Hormone on Protein Turnover in the Fasting and Fed State in Adolescents with Crohn Disease. Journal of Pediatric Endocrinology and Metabolism. 2011. 24(9-10): 633-640. PMID: 22145448

18. Richards GE, Thomsett MJ, Boston B, DiMeglio LA, Shulman DI, Draznin M. Natural History of Idiopathic Diabetes Insipidus. Journal of Pediatrics. 2011. 159(4):566-70. PMID: 21592500

19. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottleib PA, Greenbaum CJ, Marks JB, Monzavi R, Moran AM, Raskin P, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: A Randomised Double-Masked Controlled Trial. The Lancet. 2011. 378(9789):412-9. PMC3462593

20. Wherrett D, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottleib PA, Greenbaum CJ, Marks JB, Monzavi R, Moran AM, Orban T, Raskin P, Russell WE, Schatz D, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet GAD Study Group. Antigen-Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in Patients with Recent-Onset Type 1 Diabetes: A Randomised Double-Masked Controlled Trial. The Lancet. 2011. 378(9788):319-27. PMC3580128